A botched acquisition deal and unrest among company investors amid plummeting stocks have plagued Illumina, which was once part of the biotech big leagues that dominated the field of gene sequencing. Now, in fear of losing its ground to other players in the space, it has received a European Commission order to divest Grail, and […]
Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, has closed a $10m Series A financing round, led by Mercia. The new funding will be used to scale operations and continue development of its DNA synthesis platform, gSynth. Camena Bioscience is the first company to offer the enzyme-based DNA synthesis […]
HuidaGene Therapeutics, a clinical-stage genome-editing company, says the National Science Review has published data from its study of the world’s first DNA base editor converting guanine to cytosine/thymine (pyrimidine), or G-to-Y. The company has filed an international patent application for the glycosylase-based guanine base editor (gGBE) and owns the exclusive global rights to the underlying […]
Most chromosomes have been around for millions of years. However, researchers from the Stowers Institute for Medical Research have revealed the dynamics of a new, very young chromosome in fruit flies that is similar to chromosomes that arise in humans and is associated with treatment-resistant cancer and infertility. The researchers say the findings may lead […]
Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in […]
20Med Therapeutics, a company working on non-viral delivery and development of gene therapies and vaccines, and Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, have announced that both parties will collaborate on establishing a novel vaccination platform that combines Touchlight’s rapid enzymatic doggybone DNA platform with 20Med Therapeutics’ bioresponsive […]
A team of scientists led by Kei-ichi Takata from the Center for Genomic Integrity (CGI) within the Institute for Basic Science (IBS) in South Korea, has discovered a new type of DNA repair mechanism that cancer cells use to recover from next-generation cancer radiation therapy. Ionizing radiation (IR) therapy is frequently used in the treatment […]
The concept of de-extinction has been around for many years. Once considered a fanciful idea, recent advancements in technology – notably CRISPR – have made bringing back extinct animals such as mammoths an extremely feasible proposition that investors are willing to put their money into, with an aim of reversing and preventing biodiversity loss. The […]
Debiopharm, an independent Swiss-based, biopharmaceutical company, has obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk. FT-3171 was developed by Forma Therapeutics, which was acquired by Novo Nordisk in 2022, and is currently in late preclinical development. FT-3171 (Debio 0432) could […]